Natural products have provided critical starting points for the development of a majority of the antibacterial drugs listed as essential medicines by the World Health Organization. During the period from about 1940 to 1960, sometimes described as the golden age of antibiotics research, academic and industrial laboratories identified the natural products that went on to define many of the major classes of modern antibiotics 1 . Few if any natural products prove to be optimal for safety, efficacy or oral use in humans, however, for these were probably not evolutionary pressures for the microbes in which they developed. For six decades a primary tool by which new antibiotics have been discovered and manufactured is semisynthesis, or the chemical modification of natural products derived from fermentation. Semisynthesis is inherently limited because it is challenging to modify structurally complex natural products selectively, and typically few positions of any given scaffold can be modified effectively 2, 3 . Macrolide antibiotics (macrocyclic lactones with one or more pendant glycosidic residues), which have proven to be safe and effective for use in treating human infectious diseases such as community-acquired bacterial pneumonia, gonorrhoea and others, provide a compelling case in point. Since the discovery of erythromycin from a Philippine soil sample in 1949 4 , in spite of extraordinary efforts leading to fully synthetic [5] [6] [7] [8] and modified biosynthetic routes [9] [10] [11] [12] to macrolide antibiotics, all members of this class approved or in clinical development for use in humans have been manufactured by chemically modifying erythromycin (erythromycin itself is unstable in the stomach, and rearranges to form a product with gastrointestinal side-effects) 13 . Thus, azithromycin is prepared from erythromycin in four steps 14 , clarithromycin requires six steps 15 , and the advanced clinical candidate solithromycin is currently produced from erythromycin by a 16-step linear sequence ( Fig. 1 ) 16, 17 . New macrolides are badly needed, for resistance to approved macrolide antibiotics such as clarithromycin and azithromycin is now widespread in both hospitals and the community [18] [19] [20] . Here we present a practical, fully synthetic platform for the preparation of macrolide antibiotics, providing both a discovery engine for structurally novel antibiotic candidates that would be difficult or impossible to obtain from erythromycin, as well as a basis for their eventual manufacture. Using simple building blocks and a highly convergent assembly process, we have prepared more than 300 structurally diverse macrolide antibiotic candidates, as well as the approved drug telithromycin and the clinical candidate solithromycin. We have identified molecules with diverse macrocyclic scaffolds that exhibit potent activities against bacterial strains resistant to erythromycin, azithromycin and other current antibiotics of different classes.
Synthesis of 14-membered azaketolides
To illustrate our approach to the synthesis of macrolide antibiotics, we begin by detailing a route to new and highly active hybrid antibiotics, 14-membered azaketolides (Fig. 2) , and then show how the approach can be easily expanded to subsume many other active macrolide scaffolds, with broad latitude for substitutional variation. Ketolides replace the C3-cladinose carbohydrate residue of erythromycin with a carbonyl group, a chemical modification that allows them to evade certain inducible forms of macrolide resistance 21, 22 , whereas the azalide azithromycin incorporates a nitrogen atom within an expanded (15-membered) macrolactone ring, features that have been proposed to impart favourable pharmacological properties, including increased efficacy against certain Gram-negative pathogens 23, 24 . The hybrid 'azaketolides' , or macrolides that contain both a C3 carbonyl group and a nitrogen atom within the macrolactone ring, have been little explored; one such compound has been reported and was found to be essentially inactive 25 . We were particularly interested in 14-membered azaketolides that would arise from formal replacement of the carbonyl group at position C9 The chemical modification of structurally complex fermentation products, a process known as semisynthesis, has been an important tool in the discovery and manufacture of antibiotics for the treatment of various infectious diseases. However, many of the therapeutics obtained in this way are no longer effective, because bacterial resistance to these compounds has developed. Here we present a practical, fully synthetic route to macrolide antibiotics by the convergent assembly of simple chemical building blocks, enabling the synthesis of diverse structures not accessible by traditional semisynthetic approaches. More than 300 new macrolide antibiotic candidates, as well as the clinical candidate solithromycin, have been synthesized using our convergent approach. Evaluation of these compounds against a panel of pathogenic bacteria revealed that the majority of these structures had antibiotic activity, some efficacious against strains resistant to macrolides in current use. The chemistry we describe here provides a platform for the discovery of new macrolide antibiotics and may also serve as the basis for their manufacture.
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of ketolides with an amino group, a transformation that would not be feasible by semisynthesis.
An overview is helpful, as it emphasizes our synthetic strategy. Eight simple building blocks (1-8), two of which are commercially available and six of which are synthesized in sequences of 3-6 steps in 30-150-g amounts, are assembled in a highly convergent manner (Fig. 2) . As depicted, building blocks 1-3 are transformed by a seven-step sequence featuring two convergent coupling reactions to provide a key left-hand intermediate (15, an amine) in 57% yield, while building blocks 4-7 are transformed in a seven-step sequence featuring three convergent coupling reactions to form a key right-hand intermediate (22, a ketone) in 58% yield. (Here left and right refer to the position in the graphical representation of the target molecule, Fig. 2a .) The left-and righthand intermediates are then joined in a highly stereoselective and efficient reductive coupling reaction (82% yield, diastereomeric ratio (d.r.) > 20:1) that also serves to remove the benzoate protective group within the desosamine residue. The next step is the key macrocyclization reaction, for which we employ a method developed by Boeckman et al. in the context of their approaches towards the natural products diplodialide A (a 10-membered macrolactone), kromycin (a 14-membered macrolactone) and ikarugamycin (a 17-membered macrolactam) 26, 27 . We found that thermolysis of intermediate 23 (1 mM in chlorobenzene) at 132 °C afforded the macrolactone 24 in 78% yield (1-g scale). There are a number of notable features of this transformation, not least its efficacy and, as we will show, generality. Many pioneering efforts to synthesize macrolide antibiotics failed at the stage of macrocyclization; successful macrocyclizations were shown to require carefully designed, rigidifying protective group strategies 28 . We believe that the success of the present cyclization (which we note occurs in the presence of a free secondary amine as well as another secondary alcohol) is attributable in part to the rigid structuring induced by the cyclic carbamate function on the left-hand side of the molecule, which we suspect brings the putative acyl ketene function (produced from the dioxolenone function upon thermolysis) and the reactive secondary alcohol into favourable proximity. A single operation then transforms the product of macrocyclization into a fully synthetic antibiotic candidate (25) while incorporating the final building block using Sharpless' optimized conditions for azide-alkyne dipolar cycloaddition 29 (8, 86% yield) . This final step is by design a convergent coupling reaction, and permits optimal latestage diversification of a key side-chain residue that is known to occupy a novel pocket in the bacterial ribosome [30] [31] [32] [33] [34] . Aspects of certain steps before the macrocyclization reaction merit brief discussion (see Fig. 2 ). The key aldol coupling reaction that unites building blocks 1 35 and 2
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, initiating the synthesis of the left-half intermediate, involves new methodology that was developed specifically for the present purpose (though it proves to be a general transformation) and proceeds in 98% yield on a 33-g scale to form a single, crystalline diastereomer 36 . In a subsequent step, which transforms the pseudoephenamine amide function into a methyl ketone in one operation, the pseudoephenamine auxiliary is recovered by a simple aqueous extraction procedure in 92% yield. The convergent coupling reaction that unites building blocks 4 and 5 to begin the construction of the right-half intermediate is based on a palladium-catalysed ene reaction developed by Mikami and co-workers, and proceeds in 93% yield and 92% enantiomeric excess (e.e.) 37 . Two convergent coupling reactions follow three linear functional group interconversions, the first coupling being a Mukaiyama 38 aldol reaction (to incorporate building block 6 39 ) whose diastereoselectivity was observed to be dependent upon the reaction conditions. The conditions employed here (magnesium bromide etherate as Lewis acid, triethylamine as base, dichloromethane as solvent, and a reaction temperature of −78 °C) provided maximum selectivity (d.r. > 20:1, 91% yield) for the desired syn-aldol product. The next convergent coupling reaction introduced the protected desosamine carbohydrate residue and for this purpose we employed the thioglycoside 7 40, 41 , a donor very similar to that employed by Woodward et al. in their synthesis of erythromycin 5 .
In the present case, we found that the use of a benzoyl group to shield the secondary alcohol on the glycosidic donor in lieu of methoxycarbonyl improved the yield and diastereoselectivity of the glycosidation reaction. The overall yield of the fully synthetic azaketolide antibiotic candidate 25 was 32% from initial building blocks 1 and 2 (a 10-step sequence) or 32% from initial building blocks 4 and 5 (also a 10-step sequence).
Synthesis of 15-membered azaketolides
By design, the convergent building block strategy we employ enables rapid access to structurally related scaffolds; for example, synthesis of a 15-membered hybrid azaketolide scaffold comprising structural Article reSeArcH features of both the azalide antibiotic azithromycin and the ketolide clinical candidate solithromycin (Fig. 3) required modification of just three of the eight building blocks that were used to assemble 14-membered azaketolides (Fig. 2) . The left-hand amine intermediate (15) was the same in both 14-and 15-membered azaketolide scaffold syntheses and thus construction of the 15-membered azaketolides simply required access to the homologated right-hand intermediate, aldehyde 35.
Here, too, we employed a seven-step sequence (38% yield) featuring three convergent coupling reactions to assemble four simple building blocks. The first coupling, which unites building blocks 26 42 and 27 43, 44 to form the tertiary alcohol 29, emerged only after extensive experimentation, in which we discovered that incorporating the large tert-butyldiphenylsilyl protective group within component 27 was key to achieve high diastereoselectivity. After two subsequent functional group interconversions, building blocks 6 (as before) and 28 (the original glycosyl donor of Woodward et al. 5 , which proved to be effective in this scaffold synthesis) were incorporated by successive convergent coupling reactions. Two linear steps then provided the right-hand (35) in the presence of sodium cyanoborohydride proceeded without detectable epimerization to afford the macrocyclization precursor 36 in 86% yield. Thermolysis of 36 at 132 °C in chlorobenzene then afforded the 15-membered macrolide 37 in 94% yield on a 1.9-g scale. Incorporation of the final building block (8, as before) and cleavage of the methoxycarbonyl protective group were achieved in a single, final step to provide the azaketolide antibiotic candidate 38. The overall yield of the fully synthetic macrolide 38 (FSM-20707, see below) was 43% from initial building blocks 1 and 2 (a 10-step linear sequence) or 33% from initial building blocks 26 and 27 (also a 10-step linear sequence).
Synthesis of 14-membered ketolides
We next adapted our convergent assembly strategy to synthesize 14-membered ketolides, a class that includes the clinical candidate solithromycin as well as the approved drug telithromycin, with the goal of preparing diverse structural analogues. Towards this end we envisioned coupling of the same right-hand intermediate employed in the synthesis of 15-membered azaketolides (aldehyde 35) with a Grignard reagent derived from hydromagnesiation of the acetylenic alcohol 42 (Fig. 4) . Intermediate 42 was obtained in one step (14:1 d.r., 85% yield) by the addition of 1-lithiopropyne (39) to ketone 40 35 in the presence of lithium (1S,2R)-1-phenyl-2-(pyrrolidin-1-yl)-1-propanolate 45 . Hydromagnesiation of 42 with cyclopentylmagnesium bromide and bis-cyclopentadienyltitanium dichloride 46 proceeded regioselectively to furnish a vinyl Grignard reagent that was captured in situ with aldehyde 35. The resulting diastereomeric mixture of allylic alcohols (obtained in 80% yield on a 3-g scale) was oxidized directly (Dess-Martin periodinane, 97%) and the α ,β -unsaturated ketone produced was desilylated (tetrabutylammonium fluoride (Bu 4 NF), 95%) to afford the keto alcohol 45. Macrocyclization, as before, then provided the 14-membered Br OTf Article reSeArcH macrolactone 46 in 66% yield (1.7-g scale). Fluorination at position C2 proceeded in 85% yield 47 . Transformation of the C12 tertiary alcohol within the latter intermediate (47) to the corresponding acyl imidazolide (carbonyl diimidazole (Im 2 CO), 1,8-diazabicyclo [5.4 .0]undec-7-ene (DBU)) and trapping with amine 49 then afforded fully synthetic solithromycin in one operation (87% yield, the methoxycarbonyl protective group was cleaved concomitantly under these conditions).
The present route to solithromycin proceeds in 14 steps and 16% yield from building blocks 26 and 27, and differs from the semisynthetic route (16 steps from erythromycin, yields not reported 16 ) in that the linker and its attached side-chain heterocycle are introduced in the final step of our synthesis and thus modification of these residues is quite facile, whereas the linker residue is introduced 6 steps before the penultimate step in the published semisynthetic route to solithromycin 16 . 
Article reSeArcH
We prepared a number of fully synthetic 14-membered ketolides by taking advantage of this feature of our synthesis to simultaneously vary the linker and side-chain heterocycle, and many of these products show potencies that are superior to solithromycin in microbiological assays (see below).
Construction of a library of macrolide antibiotics
We prepared an initial library of > 300 fully synthetic macrolide (FSM) antibiotic candidates by varying the building blocks in concert with modifying readily diversifiable elements (for example, an azido group, an amino group, a β -keto lactone function, an allyl group) that we introduced into and around the macrolide ring, a powerful tactical combination. In addition to members of the three primary macrocyclic scaffolds discussed in detail above, we prepared a number of other unique scaffolds by modifying the principal coupling components (left-and right-halves) and their modes of coupling using straightforward alternative chemical transformations (see Supplementary Information for a complete list of structures synthesized and Extended Data Figs 1-10 for exemplary schemes for their preparation). This strategy not only provided novel scaffolds to explore, but also permitted deep-seated variations of positions within these scaffolds, thus enabling access to molecules that could not be prepared using semisynthetic methods.
Microbiological testing
To evaluate our FSMs for antibiotic activity, we screened 305 of them against a panel of pathogens comprising standardized Gram-positive and Gram-negative strains (see Supplementary Information). For the most promising antibiotic candidates, the panel was expanded to include bacteria with genetically characterized resistance mechanisms to erythromycin as well as other antibiotics. These include three different strains of Staphylococcus aureus, two of them clinically isolated methicillin-resistant (methicillin-resistant Staphylococcus aureus, MRSA) pathogens, a clinically isolated strain of Streptococcus Article reSeArcH pneumoniae with both ribosome-modifying methyltransferase (ermB) and efflux (mefA) genes, and finally a clinically isolated strain of Enterococcus faecalis with an ermB gene, a strain resistant to all approved macrolides as well as vancomycin (vancomycin-resistant Enterococcus, VRE) (Fig. 5) . The data show that a majority of compounds in the library exhibit demonstrable antibiotic activity. For example, 83% of compounds in the collection displayed a minimum inhibitory concentration (MIC) ≤ 4 μ g ml −1 against wild-type S. pneumoniae, which is known to be highly susceptible to inhibition by macrolides (see Supplementary Information) . Among the most promising compounds (Fig. 5) ), a VRE with an ermB gene (MICs 1 and 2 μ g ml , respectively). Clearly, further work will be required to drive potencies in the latter two strains to clinically efficacious levels, but we believe that demonstration of even modest activity in these challenging strains by a macrolide is significant. It is interesting and encouraging to note that FSM-100573 also displays improved Gram-negative activity relative to many other macrolides; further advances in this regard would address an important area of unmet medical need 48 .
Conclusion
Employing as a design strategy the multiply convergent assembly of simple chemical building blocks, we have developed a platform of unprecedented versatility for the discovery and practical synthesis of novel macrolide antibiotics. Varying the building blocks as well as (at a later stage) diversifiable elements incorporated within them permits an almost exponential expansion of variability within any given scaffold. In addition, our work shows that variant scaffolds can be obtained by straightforward perturbations of our generalized assembly process. As with our earlier convergent synthesis of tetracycline antibiotics 49, 50 , we anticipate that many thousands of novel macrolide structures can be prepared for evaluation as potential antibiotics using the present synthetic platform. In light of this, it seems logical to conclude that developing similar convergent routes to other naturally occurring antibiotic families may accelerate the discovery of new therapeutic agents for human infectious diseases.
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